Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Eye Disorders Resource Center

Welcome to the MPR Eye Disorders Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs
Click on the subcategory below to find drug monographs for that particular area.

News

Avastin and Lucentis Equally Improve Visual Acuity in AMD

Avastin (bevacizumab) and Lucentis (ranibizumab) have similar effects on visual acuity in age-related macular degeneration (AMD).
 

RECALL: Franck's Compounding Triamcinolone Acetonide Recall

Franck's Compounding Pharmacy has recalled one additional lot of triamcinolone acetonide PF 80mg/mL.
 

Genetic Link Identified for Multiple Forms of Glaucoma

Two genomic regions have been identified that are associated with normal-pressure glaucoma (NPG) and optic nerve disease in exfoliation-syndrome glaucoma (ESG), possibly through the transforming growth factor beta (TGF-beta) signaling pathway.
 

S. Aureus, Enterotoxins ID'd in Atopic Keratoconjunctivitis

Staphylococcus aureus (S. aureus) and S. aureus-secreted enterotoxins (SE) are frequently found in patients with atopic keratoconjunctivitis (AKC), particularly in those with corneal ulceration.
 

SAFETY ALERT: Second Warning for Franck's Compounds

The FDA has received additional reports of fungal endophthalmitis (eye infections) in patients who were given Brilliant Blue G (BBG) during eye surgery since the FDA Warning to Physicians was posted on March 19, 2012.
 

New Drugs

BROMDAY

11/18/2010

Pharmacological Class: NSAID.
Active Ingredient(s): Bromfenac 0.09%, oph soln; contains benzalkonium chloride, sulfites.
Indication: Post-operative inflammation and reduction of ocular pain following cataract extraction.
 

ClinicalJobAdvisor

Loading...

More Jobs

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions